Indian Pharmaceutical Alliance Defends Section 3(d) Of Patents Act, Says Statute Not Against Incremental Innovations
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The Indian Pharmaceutical Alliance - an influential lobbying group that represents 15 leading Indian drug makers - has stridently opposed a 2009 report published by the U.S.-India Business Council that called for certain changes in the country's Patents Act